BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 10167309)

  • 1. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The generics in transplantation and the rules on their use.
    Masri M
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 12. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent cliff mitigation strategies: giving new life to blockbusters.
    Kakkar AK
    Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C
    Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent trends in brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.